A potent inhibitor of Th2-related chemokines (such as CCL17, CCL18, CCL22, and CCL26) in AD patients, dupilumab, an IL-4 receptor antagonist blocking both IL-4 and IL-13 signaling pathways, significantly improves the molecular signature of AD and exhibits a satisfactory efficacy and safety profile (5). Here, CCL26 is linked to Alzheimer disease.